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REVIEW
Abstract: Lercanidipine is a lipophilic, dihydropyridine calcium antagonist with a long
receptor half-life. Its slow onset of action helps to avoid reflex tachycardia associated with
other dihydropyridines (DHPs). It produces even and sustained blood pressure lowering with
once-daily dosing. It has equivalent antihypertensive efficacy to many other agents and is
effective as initial monotherapy or in combination. Efficacy has been demonstrated in elderly
as well as younger patients and also in the presence of other risk factors. Lercanidipine is well
tolerated with DHP-associated adverse effects occurring early in treatment. The incidence of
pedal edema and subsequent withdrawals has been found to be lower with lercanidipine than
with amlodipine or nifedipine gastrointestinal transport system. Preclinical and preliminary
clinical findings suggest lercanidipine may have beneficial effects on atherosclerosis and left
ventricular hypertrophy. The efficacy and tolerability profiles of lercanidipine make it a suitable
choice for treating hypertension in a wide range of affected patients.
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Introduction
Hypertension is a major contributor to global disease burden, occurring as an insidious
accompaniment to aging populations (Kostis 2003; WHO 2003). It is estimated to
have caused 7.1 million premature deaths in 2002 and is an ever-increasing worldwide
problem (WHO 2003). It is a well recognized risk factor for cardiovascular disease
(Chobanian et al 2003; European Society of Hypertension-European Society of
Cardiology Guidelines Committee 2003), and is often combined with other risk factors
such as smoking, obesity, and physical inactivity (WHO 2003), and it occurs
commonly with diabetes (ADA et al 2004).
Antihypertensive drugs are well known to prevent cardiovascular morbidity and
mortality. The risks of stroke and myocardial infarction decrease by about 40% and
15%, respectively, in individuals who experience long-term diastolic blood pressure
reduction of 5–6 mmHg (Collins et al 1990). Hypertension management aims to
reduce the long-term risk of cardiovascular complications, and involves lifestyle
modifications, antihypertensive drug therapy, and treatment of comorbid conditions
(European Society of Hypertension-European Society of Cardiology Guidelines
Committee 2003). The major antihypertensive drug classes (diuretics, calcium
antagonists, β-blockers, angiotensin converting enzyme [ACE] inhibitors, and
angiotensin receptor blockers) are all effective at lowering blood pressure, such that
drug choice may be governed by patient characteristics (risk profile, concomitant
disease), drug tolerability, cost of drugs, and the growing realization of the requirement
for combination therapy to achieve goal blood pressure (Cifkova et al 2003).
Calcium antagonists
Calcium antagonists are a heterogeneous group of established antihypertensive agents
that includes the phenylalkylamine, verapamil, the benzothiazepine, diltiazem, and
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the dihydropyridines (DHPs). The landmark series of
prospective trials comparing calcium antagonists with other
antihypertensive medications showed that, as a class,
calcium antagonists produce similar effects to diuretics,
β-blockers, and ACE inhibitors on cardiovascular mortality
and combined morbidity, and that they reduce stroke in
elderly hypertensive patients with isolated systolic
hypertension (ISH) (Hansson et al 1999, 2000; Brown et al
2000; ALLHAT Officers and Coordinators 2002).
The DHPs work primarily as vasodilators and have
evolved from the first generation, short-acting compounds
(eg, nifedipine and felodipine), which produced unwanted
reflex tachycardia. Modified formulations were introduced
to extend duration of action and limit adverse effects;
however, amlodipine was the first DHP with an inherently
long plasma half-life. The latest advance is the introduction
of agents with a prolonged receptor half-life (reviewed in
Messerli 2002) (Figure 1). The present review will describe
the clinical efficacy and potential benefits of one of these
newer agents, lercanidipine.
Pharmacology
Pharmacokinetics
Lercanidipine has a plasma half-life of 8–10 hours (Bang
et al 2003) but this does not relate to its duration of
antihypertensive activity. Its high membrane partition
coefficient provides a long-lasting effect at receptor and
membrane levels (Herbette et al 1998) allowing for once-
daily administration. Oral lercanidipine is maximally
absorbed after 2 hours of administration, it exhibits high
serum protein binding, and is rapidly accumulated in
arteriolar cell membranes. It is metabolized by cytochrome
P450 (CYP) 3A4 and the metabolites are eliminated in urine
and feces (Bang et al 2003). As with other DHPs, the
potential for interaction with drugs that induce or inhibit
P450 (CYP) 3A4 exists and should be considered (see
review by Bang et al 2003).
Pharmacodynamics
Preclinical studies show lercanidipine is highly selective for
vascular tissue and produces smooth muscle relaxation
through competitive binding to L-type calcium channels
(Guarneri et al 1996; Wirtz and Herzig 2004). It is highly
lipophilic and is stored within cell membranes, which
explains its slow onset of action and persistent smooth
muscle relaxant effect (Guarneri et al 1996; Sironi et al
1996a; Herbette et al 1998). The antihypertensive effect of
lercanidipine primarily occurs by peripheral and coronary
vasodilatation (Sironi et al 1996b). Lercanidipine has greater
vascular selectivity and causes less negative inotropism in
vitro than other DHPs including lacidipine, amlodipine,
felodipine, and nitrendipine (Guarneri et al 1996; Angelico
et al 1999). It does not cause significant reflex tachycardia
or other signs of sympathetic activation when given at
therapeutic doses to patients with hypertension (Omboni et
al 1998; Barbagallo M and Barbagallo SG 2000; Cavallini
and Terzi 2000; Fogari et al 2003; Grassi et al 2003).
Lercanidipine (10 mg/day) produces a smooth anti-
hypertensive effect without unfavorable hemodynamic or
sympathetic effects (Omboni et al 1998; Macchiarulo et al
2001; Motero et al 2002; Millar-Craig et al 2003).
In addition to its general antihypertensive activity,
lercanidipine has a nephroprotective effect in spontaneously
hypertensive rats (Sabbatini, Vitaioli, et al 2000) and dilates
both afferent and efferent arterioles (Sabbatini, Leonardi,
et al 2000; Sabbatini et al 2002). Lercanidipine may also
have benefits in patients with hypertension and athero-
sclerotic disease where it is able to reside in cell membranes
in the presence of high cholesterol levels (Herbette et al
1998). It has well described (in in vitro, animal, and clinical
studies) antioxidant effects affecting vasodilatation and
reducing oxidation of low-density lipoproteins (Bellosta and
Bernini 2000; Digiesi et al 2000; Incandela et al 2001;
Rachmani et al 2002; Taddei et al 2003; Versari et al 2004).
Regression of left ventricular hypertrophy has been
described with lercanidipine in patients with hypertension,
Long receptor half-life
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Long plasma half-life
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Modified formulation
eg, nifedipine GITS
Rapid-acting
eg, nifedipine
Figure 1 Evolution of dihydropyridine calcium antagonists for improved clinical
efficacy and tolerability. Abbreviations: GITS, gastrointestinal therapeutic
system.Vascular Health and Risk Management 2005:1(3) 175
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with or without diabetes (Fogari, Mugellini, et al 2000;
Seravalle et al 2002). Interestingly, lercanidipine exerted a
prolonged vasodilatory action in the microcirculation of
19 patients with hypertension, where it might protect against
target organ damage (Cesarone et al 2000).
Clinical studies
Efficacy in mild-to-moderate
hypertension
The efficacy of lercanidipine has been demonstrated in
several uncontrolled trials (10–20 mg/day) carried out in
more than 20 000 patients with mild-to-moderate hyper-
tension (Barrios et al 2002; Schwinger and Schmidt-Mertens
2002; Guillen et al 2003; Robles et al 2003; Luque et al
2004). In summary, systolic and diastolic blood pressure
reductions of 19 – 26 mmHg and 13 –15 mmHg, respectively,
were found 3 – 6 months after starting therapy.
There have been several comparisons of lercanidipine
with other antihypertensive agents (Table 1). In double-
blind/crossover studies, lercanidipine (10–20 mg/day) was
as effective as amlodipine 10 mg/day (De Giorgio et al 1999;
Pedrinelli et al 2003), felodipine (10–20 mg/day) (Romito
et al 2003), and nifedipine slow-release (40–80 mg/day)
(Policicchio et al 1997) or gastrointestinal therapeutic
system (GITS, 30–60 mg/day) formulations (Fogari,
Malamani, et al 2000; Fogari et al 2003; Romito et al 2003).
Compared with other antihypertensive drugs, lercanidipine
(10–20 mg/day) showed efficacy equivalent to atenolol
(50–100 mg/day) (Morisco and Trimarco 1997), captopril
(50–100 mg/day) (Sangiorgi et al 1997), hydro-
chlorothiazide (12.5–25 mg/day) (Notarbartolo et al 1999),
losartan (50–100 mg/day) (James et al 2002), telmisartan
(80 mg/day) (Sarafidis et al 2004), and candesartan (Aranda
et al 2000). In summary, lercanidipine reduced systolic and
diastolic blood pressure in these studies, producing a high
response rate and/or normalization of blood pressure in as
little as 4 weeks of therapy (Table 1).
Efficacy in specific populations
Elderly patients
Lercanidipine is effective in elderly patients with mild-to-
moderate hypertension. In a double-blind, placebo-
controlled study of 144 elderly patients with hypertension
(aged 60–85 years), lercanidipine 10 mg/day for 4 weeks
reduced systolic and diastolic blood pressure to a greater
extent than placebo (15 vs 7 mmHg and 10 vs 6 mmHg,
respectively, p < 0.01 for diastolic blood pressure) and
increased the response rate (59% vs 38%, p < 0.05) (Ninci
et al 1997). In an open study of 756 patients, lercanidipine
(10–20 mg/day for 8 weeks) reduced blood pressure to a
similar extent in patients under and over 65 years (Poncelet
et al 2004). Reports of 3 open studies in patients at least 60
years old show that lercanidipine produces significant
reductions of systolic, diastolic, and pulse pressure in this
patient population (Calvo et al 2002; Martell et al 2004;
Roma et al 2004).
Two large controlled studies showed that lercanidipine
(5–10 mg/day or 10–20 mg/day) is as effective as lacidipine
(2–4 mg/day), amlodipine (5–10 mg/day), or nifedipine
GITS (30–60 mg/day) at lowering blood pressure in elderly
patients with hypertension (Table 1) (Leonetti et al 2002;
Cherubini et al 2003). In elderly patients with ISH,
lercanidipine was more effective than placebo in terms of
reduction of systolic blood pressure and number of patients
responding or being normalized after 4 and 8 weeks of
therapy (p < 0.001 for all comparisons) (Barbagallo M and
Barbagallo SG 2000). A similar well designed study in 290
patients with ISH found that lercanidipine (10 mg/day) and
lacidipine (2 mg/day) were equivalent at reducing systolic
blood pressure (24 versus 22 mmHg after 16 weeks) (Millar-
Craig et al 2003).
Concomitant diseases
Several large-scale uncontrolled trials have shown that
lercanidipine is effective in antihypertensive patients with
concomitant diseases or risk factors. The ELYPSE study of
lercanidipine in daily clinical practice comprised 9059
patients with mild-to-moderate hypertension and a range
of additional risk factors such as obesity, hyper-
cholesterolemia, smoking, and diabetes mellitus (Barrios
et al 2002). The authors found that 3 months of treatment
with lercanidipine was effective at reducing blood pressure
across this broad range of patients. Similar findings were
achieved in an observational 6-week study of 32 345 patients
with mild-to-moderate hypertension and concomitant
diseases such as lipid disorders, diabetes mellitus, coronary
heart disease, and heart failure (Marx et al 2004). An open
study in 3175 hypertensive patients with various levels of
cardiovascular risk found that lercanidipine was effective
across all risk levels and appeared most effective in those
with the highest risk (Barrios et al 2004b). A further study
in 2793 patients with hypertension who were also
overweight showed lercanidipine efficacy is not adverselyVascular Health and Risk Management 2005:1(3) 176
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Table 1 Efficacy and tolerability of lercanidipine compared with other antihypertensive drugs in patients with mild-to-moderate
hypertension
Study Responding
design/ SBP/DBP SBP/DBP (normalized)
duration N/Age Dosages at baseline at study end at 4 weeks Overall Adverse
Study (w) (y) (mg/day) (mmHg) (mmHg) (%) efficacy events
Comparison with calcium antagonists
Pedrinelli sb, co / 22 2  / 48 ± 5 L 20 L 146 ± 16 / 93 ± 13 L 138 ± 9 / 86 ± 9a NR L ≡ AL  < A (leg
et al 2003 A 10 A 148 ± 17 / 95 ± 11 A 137 ± 13 / 84 ± 9a edema)b
De Giorgio db, co / 42 0  / 55 ± 9c L 20 L 162 ± 20 / 101 ± 5 L 141 ± 24 / 88 ± 10d L 86 (86) (33) L ≡ AL  ≡ A
et al 1999 A 10 A 166 ± 19 / 104 ± 6 A 152 ± 16 / 94 ± 9d A 56
Romito db, p / 8e 325 / 31–74 L 10 L 155 ± 11 / 99 ± 3 L 141 ± 13/ 87 ± 7f L ≡ NG ≡ FL  ≡ NG ≡ FL  ≡ NG < Fg
et al 2003 NG 30 NG 155 ± 12 / 99 ± 3 NG 142 ± 10 / 86 ± 7f
F 10 F 155 ± 12 / 99 ± 3F  1 3 8  ± 10 / 85 ± 7f
Policicchio db, p / 8e 130 / 18–70 L 10 L 163 ± 12 / 101 ± 5 L 151 ± 13 / 91 ± 9h L 58 (51) L ≡ NS L ≡ NS
et al 1997 NS 40 NS 163 ± 14 / 101 ± 4 NS 151 ± 14 / 91 ± 8h NS 63 (53)
Fogari db, p / 48e 60 / 30–65 L 10 L 159 ± 11 / 101 ± 6 L 137 / 85a NR L ≡ NG NRi
et al 2003 NG 30 NG 159 ± 10 / 101 ± 5 NG 21 / 15a
Fogari db, p / 12e 60 / 36–70 L 10 L 163 ± 5 / 98 ± 4 L 144 ± 5 / 86 ± 4a NR L ≡ NG L < NG (ankle
et al 2000a NG 30 NG 162 ± 6 / 97 ± 4 NG 144 ± 5 / 86 ± 3a edema)j
Comparison with other antihypertensive drug classes
Morisco db, p / 8e 217 / 18–70 L 10 L 157 ± 11 / 100 ± 3 L 145 ± 12 / 90 ± 8d L 71 (65) L ≡ AT L ≡ AT
et al 1997 AT 50 AT 157 ± 11 / 100 ± 4 AT 142 ± 13 / 88 ± 7d AT 78 (76)
Sangiorgi db, p / 12e 115 / 18–80 L 10 L 161 ± 10 / 100 ± 3 L 147 ± 10 / 89 ± 7d L 75 (81) L ≡ CL  ≡ C
et al 1997 C 50 C 159 ± 10 / 100 ± 3 C 148 ± 11 / 91 ± 7d C 73 (74)
Notarbartolo db, p / 24e 52 / 18–70 L 10 L 159 ± 13 / 105 ± 5 L 143 ± 7 / 92 ± 7d L 65 (54) L ≡ HL  < H (lipid
et al 1999 H 12.5 H 158 ± 14 / 103 ± 5 H 146 ± 10 / 93 ± 7d H 58 (54) changes)
James db, p / 16e 562 / 18–75 L 10 L 163 ± 15 / 101 ± 5 L 148 ± 16 / 88 ± 7L  ≈ 80 (71) (16w) L ≡ LO L ≡ LO
et al 2002 LO 50 LO 162 ± 13 / 101 ± 5 LO 144 ± 15 / 88 ± 8L O  ≈ 80 (65) (16w)
Sarafidis NR / 16 20 / 53 ± 9 L 10 L 165 ± 8 / 102 ± 2 L 151 ± 9/ 97 ± 4k L NR (20) (8w) L ≡ TN R
l
et al 2004 T 80 T 166 ± 8 / 103 ± 5 T 152 ± 8 / 96 ± 4k T NR (20) (8w)
Aranda open / 32 338 / 55 L 10 L 162 ± 11 / 97 ± 9 L 135 / 82m NR L ≡ CA L ≡ CA
et al 2000 CA 16 CA 161 ± 10 / 96 ± 7 CA 133 / 82m
Comparative studies in the elderly
Cherubini db, p / 24e 324 / ≥ 65 L 5 L 167 ± 11 / 98 ± 5 L 140 / 80f L / NG > LA (24w)n L ≡ LA ≡ NG L ≡ LA / NGo
et al 2003 LA 2 LA 168 ± 12 / 98 ± 4 LA 142 / 81f
NG 30 NG 167 ± 11 / 97 ± 4 NG 138 / 79f
Leonetti db, 828 / ≥ 60 L 10 L 170 ± 10 / 97 ± 6 L 140 / 83p L ≡ LA ≡ AL  ≡ LA ≡ AL  ≡ LA < Aq
et al 1999 p / 26–104e LA 2 LA 170 ± 10 / 97 ± 6 LA 141 / 83p
A 5 A 171 ± 11 / 97 ± 7 A 141 / 82p
a p < 0.001 versus baseline.
b p = 0.006.
c 57 ± 10 years in other treatment arm.
d Values for first 4-week treatment period (p < 0.01 versus baseline).
e Dosages doubled after 4 weeks if unsatisfactory response (2 weeks in Cherubini et al, 8 weeks in James et al).
f p < 0.01 versus baseline.
g p < 0.05.
h Values for first 4 weeks of treatment (p < 0.001 versus baseline).
i Sustained sympathetic activation with chronic NG therapy (p < 0.05 versus baseline).
j Ankle edema significantly greater with NG (p < 0.001 versus L).
k Values for first 8 weeks of treatment (p < 0.001 versus baseline).
l Neither drug affected insulin resistance.
mValues for first 6 weeks of treatment.
n p < 0.001 between treatment groups in numbers of responding and normalized patients.
o Incidence of adverse drug reactions was lowest for L.
p Values are at 6 months (p < 0.01 versus baseline). AT or enalapril (plus diuretic, if required) was added after 8 weeks in 22%–29% of patients with an unsatisfactory
response.
q Higher rates of edema, edema-related symptoms, and early edema-related discontinuation with A compared with L and LA (p < 0.001).
Abbreviations: A, amlodipine; AT, atenolol; BP, blood pressure; co, crossover; C, captopril; CA, candesartan; DBP, diastolic BP; db, double blind; H, hydrochlorothiazide;
LA, lacidipine; L, lercanidipine; LO, losartan; NE, norepinephrine; NG, nifedipine gastrointestinal therapeutic system; NR, not reported; NS, nifedipine slow-release
formulation; p, parallel; sb, single blind; SBP, systolic BP; T, telmisartan.Vascular Health and Risk Management 2005:1(3) 177
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affected by this cardiovascular risk factor (Barrios et al
2004a).
Lercanidipine monotherapy (10 or 20 mg/day) was also
effective in a randomized double-blind study of 40 patients
with hypertension and type 2 diabetes mellitus where it did
not adversely affect glucose homeostasis (Viviani 2002). In
a smaller open study in 34 similar patients, lercanidipine
(10 mg/day) replaced β-blocker therapy in patients not
controlled by combination of an ACE inhibitor and
β-blocker, and significantly reduced mean arterial pressure
and glycosylated hemoglobin which the authors attributed
to decreased vascular resistance (Cleophas et al 2001).
Lercanidipine (10 mg/day) was found to produce a similar
reduction in insulin resistance to telmisartan (80 mg/day)
in a study of 20 patients with mild-to-moderate hypertension
(Sarafidis et al 2004).
Lercanidipine (10 mg/day) did not adversely affect
proteinuria in 42 patients with hypertension and diabetes
who also had chronic renal failure when added to existing
but inadequate therapy with an ACE inhibitor or angiotensin
receptor blocker (Robles et al 2004). Significantly,
lercanidipine (10–20 mg/day over 9–12 months) was found
to reduce blood pressure and reduce albumin excretion rate
in a randomized, double-blind study of 277 patients with
hypertension, diabetes, and microalbuminuria, producing a
similar result to ramipril 5–10 mg/day (Dalla Vestra et al
2004). Most recently, lercanidipine (10 mg/day for 6 months)
produced significant reductions in blood pressure,
cholesterol, and triglyceride levels in 203 patients with
hypertension and chronic renal failure, previously treated
with ACE inhibitors or angiotensin receptor blockers.
Furthermore, creatinine clearance was increased and
proteinuria reduced adding further support to a role for
lercanidipine in improving renal function (Robles et al 2005).
Following unsuccessful therapies or used in
combination therapy
Two daily practice studies of lercanidipine included a large
proportion of patients (66% and 69%) who had achieved a
poor response or complained of adverse events when treated
with other antihypertensive medications (Barrios et al 2002;
Schwinger and Schmidt-Mertens 2002). In one of the
studies, lercanidipine was given as monotherapy and
produced significant blood pressure reduction over 3 months
(p < 0.001 versus baseline) with 64% achieving diastolic
blood pressure lower than 90 mmHg (Barrios et al 2002).
In the other study, it was equally effective when given as
monotherapy or combined with other antihypertensive
agents (Schwinger and Schmidt-Mertens 2002).
The efficacy of lercanidipine as add-on therapy has been
shown in several open studies. In a study of 756 hypertensive
patients, lercanidipine (10 mg/day) reduced blood pressure
over 8 weeks as monotherapy or as combination therapy
(Poncelet et al 2004). Lercanidipine (10mg/day) is also
effective when combined with ACE inhibitor or angiotensin
receptor blocker therapy (Guillen et al 2003; Robles et al
2004) and reduces blood pressure more than β-blocker plus
ACE inhibitor combination therapy (Cleophas et al 2001)
in patients with diabetes mellitus and hypertension. In one
study of 80 patients with hypertension resistant to
monotherapy (including β-blockers, ACE inhibitors, or
diuretics), lercanidipine (10 mg/day) or nitrendipine
(10 mg/day) as add-on therapy produced significant
decreases in blood pressure after 4 weeks and approximately
90% of patients were normalized in each group at 12 weeks
(Rengo and Romis 1997).
Several other antihypertensive drugs have been
successfully added to lercanidipine monotherapy. For
example, combining lercanidipine with hydrochlorothiazide
or telmisartan increased the rate of blood pressure
normalization in patients where an unsatisfactory response
to lercanidipine monotherapy was observed after either 4
or 8 weeks therapy (Policicchio et al 1997; Sarafidis et al
2004). Similarly, lercanidipine plus candesartan therapy was
found to be effective in 70% of patients who had not
responded to 6 weeks of monotherapy with either drug
(Aranda et al 2000).
Tolerability and patient compliance
A pooled analysis of 20 randomized, double-blind studies
shows that adverse events were reported by 11.8% of 1317
lercanidipine-treated patients (10–20 mg/day) versus 7.0%
in those who received placebo (227) for 1 – 52 weeks of
treatment (Leonetti 1999). Most adverse events occurred
within the first 4 weeks of treatment and there were only
slight differences from placebo when lercanidipine was
given at its starting dose of 10 mg/day and then titrated
to higher dosages. Adverse events with lercanidipine
10 mg/day included flushing (1.1% vs 0.4% for placebo),
ankle edema 0.9% vs 1.3%), palpitations (0.6% vs 0.4%),
headache (2.3% vs 1.3%), vertigo (0.4% vs 0.4%), and
asthenia (0.4% vs 0.4%). The incidence of adverse events
in elderly patients was 5.70%, which compared well with
younger patients (6.60%) (Leonetti 1999). An analysis ofVascular Health and Risk Management 2005:1(3) 178
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14 placebo-controlled, double-blind trials (1850 patients
with hypertension or stable angina treated for up to 18
weeks) confirmed that adverse events with lercanidipine
(10–20 mg/day) are generally mild-to-moderate (Hollenberg
2002). Headache (5.6%), edema (2.4%, tachycardia (2.1%),
flushing (2.0%), palpitations (1.7%), rhinitis (1.3%), and
hypokalemia (1.2%) were the most frequently-reported
treatment-emergent adverse events compared with headache
(3.8%), hypokalemia (1.3%), and hyperuricemia (1.1%)
with placebo.
Lercanidipine was well tolerated in all of the uncontrolled
studies and in the controlled studies reported in Table 1. It
produced no significant heart rate changes, while most
adverse events were the result of vasodilatation early in
treatment. Lercanidipine also compared well against
amlodipine, felodipine, and nifedipine GITS (Table 1).
Specifically, objective assessments have shown that
lercanidipine produces less pedal edema than nifedipine
GITS (Fogari, Malamani, et al 2000) and amlodipine
(Figure 2) (Leonetti et al 2002; Lund-Johansen et al 2003;
Pedrinelli et al 2003). The incidence of edema was also low
in a general practice study of 8981 hypertensive patients who
received lercanidipine combined with other antihypertensive
agents (the incidence was lowest when lercanidipine was
given with an ACE inhibitor) (Mallion et al 2004). The
comparative tolerability of lercanidipine and other DHPs
were investigated in an open study of 125 patients with
hypertension and drug-specific adverse events. Lercanidipine
(10–20 mg/day for 4 weeks) produced significant reductions
in edema, flushing, headache, rash, and dizziness when it
was switched from previous treatment with amlodipine,
nifedipine GITS, felodipine, or nitrendipine (p < 0.001)
(Borghi et al 2003). Weir has commented that the 2.4%
incidence of edema found with lercanidipine (10–20 mg/day)
in a pooled analysis (Hollenberg 2002) contrasts well with
incidences of 6%–29% found in studies of other DHPs
(Hollenberg 2002; Weir 2003).
Reported withdrawal rates with lercanidipine are low or
similar to placebo (Barbagallo M and Barbagallo SG 2000;
Barrios et al 2002; Schwinger and Schmidt-Mertens 2002).
This is most probably related to its good tolerability –
withdrawals due to edema are less with lercanidipine than
with amlodipine (Leonetti et al 2002; Lund-Johansen et al
2003) and nifedipine GITS (Romito et al 2003).
Patient support/disease
management programs
Official organizations have recently re-issued their
guidelines on hypertension (Chobanian et al 2003; European
Society of Hypertension-European Society of Cardiology
Guidelines Committee 2003; WHO 2003) and readers may
consult these documents to update on diagnosis, evaluation,
and non-pharmacological approaches to treatment. There
is general agreement for drug intervention if systolic/
diastolic blood pressures are greater than 140/90 mmHg
(high risk groups may be treated at lower levels) and that
first-line therapy may comprise any of the 5 major drug
classes (Stergiou and Salgami 2004), largely because of their
equivalent blood pressure lowering ability that has the
greatest benefit (European Society of Hypertension-
European Society of Cardiology Guidelines Committee
2003).
Diuretics may be favored for their low cost and extent
of outcome data (Collins et al 1990; ALLHAT Officers and
Coordinators 2002; Chobanian et al 2003); even though the
results of the ALLHAT study do not support their prevailing
role in terms of prevention of coronary events or increased
survival (ALLHAT Officers and Coordinators 2002).
Moreover, diuretics have adverse metabolic effects and may
affect male sexual function, which may be important
limitations for their chronic use (Stergiou and Salgami
2004). Assuming equal blood pressure lowering efficacy
across all drug classes, the decision on which drug to
prescribe may come down to its likely adverse events and
the individual patient’s risk profile (eg, age, target organ
damage, concomitant diseases). With regard to calcium
antagonists, these are metabolically neutral and may be
favored across a wide range of patients with hypertension,
including the elderly, those with ISH, angina pectoris,
diabetes mellitus, peripheral vascular disease, carotid
atherosclerosis, and during pregnancy (European Society
of Hypertension-European Society of Cardiology
Guidelines Committee 2003).
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Figure 2 Amlodipine produces significantly more leg edema than lercanidipine
after 2 weeks therapy in patients with mild to moderate hypertension
(p = 0.006) (Pedrinelli et al 2003).
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Combination therapy is appropriate in more than half of
patients with hypertension (Stergiou and Salgami 2004),
and calcium antagonists may be combined with any of the
other 4 drug classes (Cifkova et al 2003). Combination
therapy is most often required in elderly patients and those
with diabetes (Cifkova et al 2003; ADA 2004); therefore,
calcium antagonists offer a reliable choice in these patients
and in others with concomitant cardiovascular risks. Third
generation agents such as lercanidipine circumvent the
problems faced with other calcium antagonists, such as
uneven therapeutic effect and reflex sympathetic and
vasodilator adverse effects (Kostis 2003), and this may
improve patient compliance (Weir 2003). Figure 3 provides
a clinical summary of lercanidipine based on its intrinsic
properties, clinical trial results and applicability to latest
guidelines.
Conclusion
Lercanidipine exhibits a slow onset of action, which helps
to avoid reflex tachycardia, and produces an even and
sustained reduction in blood pressure. Preclinical and
clinical findings suggest lercanidipine may have protective
effects on the kidneys, cardiovascular system, and target
organs. The antihypertensive action of lercanidipine is
Figure 3 Clinical summary of lercanidipine in hypertension. All features and comments are derived from referenced information in the text. Abbreviations: ACE,
angiotensin converting enzyme; AEs, adverse events; DHP, dihydropyridine; ISH, isolated systolic hypertension.
Antihypertensive efficacy 
Monotherapy 
• Equivalent to other DHPs 
• Equivalent to other 
antihypertensive drug classes 
• First line or following other 
(unsuccessful) therapy 
Combination therapy 
• Effective in combination as new or 
add-on therapy 
Elderly
• As effective as other DHPs 
• Effective in ISH 
Renal disease 
• Improves kidney function 
Diabetes 
• Effective with no effect on glucose, 
or insulin resistance and reduction 
in albumin excretion 
• Can be given with ACE inhibitor 
therapy
Other risk factors 
• Effective in presence of obesity, 
hypercholesterolemia, smoking 
Key pharmacologic features 
High lipophilicity 
• Prolonged receptor time 
• Sustained vasodilatation 
(smooth antihypertensive 
action, target organ protection) 
• Minimal sympathetic activation 
• Low propensity for typical DHP 
AEs 
Afferent and efferent arteriolar 
dilatation 
• Possible nephroprotective 
effect? 
Antioxidant effect 
• Antiatherosclerotic and 
cardioprotective benefits? 
LERCANIDIPINE
Tolerability 
Adverse events 
• Well tolerated with lower incidence of AEs than older DHPs 
• Observed mostly early in treatment 
• Less pedal edema than older DHPs 
• Similar across all age groups Vascular Health and Risk Management 2005:1(3) 180
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equivalent to many other antihypertensive agents, and it is
equally effective in young and old patients and in the
presence of other risk factors, including patients with renal
dysfunction and/or type 2 diabetes. It is suitable for use as
monotherapy or in combination with other agents, in line
with current treatment guidelines. Lercanidipine is well
tolerated in all age groups and DHP-associated adverse
effects occur primarily in the first 4 weeks of treatment.
The incidence of pedal edema and subsequent withdrawals
has been found to be lower with lercanidipine than with
amlodipine or nifedipine GITs. The favorable efficacy and
safety profile of lercanidipine makes it a flexible choice for
antihypertensive treatment across a broad range of patients.
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